New Aceclidine Eye Drop Approved to Restore Near Vision Without Glasses

The landscape of presbyopia treatment just changed significantly. On July 31, 2025, the FDA approved VIZZ (aceclidine 1.44% ophthalmic solution) — the first and only aceclidine-based eye drop in the United States designed to temporarily correct near vision loss in presbyopic adults.

How VIZZ Works
VIZZ employs a pupil-selective miotic mechanism. By gently reducing pupil size, it creates a "pinhole effect" that improves depth of focus and enhances near vision for up to 10 hours — all from a single daily drop. Importantly, it achieves this without significantly impacting the eye's focusing muscles or impairing distance vision.
 

What This Means for Patients

• Acts as a non-invasive alternative to reading glasses

• Offers half-day near-vision clarity with ease and convenience

• Presents a vision correction option with minimal reliance on multifocals or bifocals

A Growing Family of Vision Solutions
The presbyopia-correcting eye drop market is rapidly evolving. Other recently approved options include:

• Qlosi (pilocarpine 0.4%, preservative-free)

• Vuity (pilocarpine 1.25%)
  And Brimochol PF (a combination of carbachol and brimonidine) is currently under FDA review, with a decision expected in early 2026.